title: Cell clonality in hypereosinophilic syndrome: what pathogenetic role?
abstract: OBJECTIVE
  Idiopathic hypereosinophilic syndrome (HES) is a heterogeneous disorder, including either a myeloproliferative or a lymphoproliferative variant (l-HES). In l-HES, T-lymphocytes could be involved in the pathogenesis through several cytokines, including IL5.
  
  
  METHODS
  We assayed both TCR Beta- and delta-rearrangements by fluorescent PCR, characterizing 14 patients affected by HES. Lyn activation (a src-kinase involved in the IL5 pathway) was also tested in 6 cases.
  
  
  RESULTS
  FIP1L1-PDGFRa was detected in 4 cases (28.6%); a clonal TCR was found in 10 cases (71.4%), including cases FIP1L1-PDGFRalpha-positive; four cases did not show any molecular marker. In this series, levels of IL5, IL4, IL2 and gammaIFN were measured, without any significant difference among different subgroups. All pathological samples tested did not show Lyn activation. Immunophenotype was also characterized: only one case showed an atypical CD3-/CD4+ population in the bone marrow.
  
  
  CONCLUSIONS
  This study would suggest that a real distinction between m- and l-HES is not wholly convincing and that clonal T-cell expansion could not be the "primum movens" but an epiphenomenon in HES.
authors.affiliation: Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara, Pisa Italy. s.galimberti@med.unip.it
authors.forename: S
authors.initials: S
authors.lastname: Galimberti
authors.forename: E
authors.initials: E
authors.lastname: Ciabatti
authors.forename: F
authors.initials: F
authors.lastname: Ottimo
authors.forename: A
authors.initials: A
authors.lastname: Rossi
authors.forename: L
authors.initials: L
authors.lastname: Trombi
authors.forename: G
authors.initials: G
authors.lastname: Carulli
authors.forename: G
authors.initials: G
authors.lastname: Cervetti
authors.forename: L
authors.initials: L
authors.lastname: Matti
authors.forename: G
authors.initials: G
authors.lastname: Bianchi
authors.forename: M
authors.initials: M
authors.lastname: Petrini
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D016207:Cytokines / Q000032:analysis / Q000235:genetics*; D004804:Eosinophils / Q000145:classification* / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000235:genetics / Q000276:immunology* / Q000503:physiopathology; D000068877:Imatinib Mesylate; D007155:Immunologic Factors / Q000494:pharmacology; D016898:Interferon-alpha / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000097:blood*; D010879:Piperazines / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000097:blood*; D012189:Retrospective Studies; D013601:T-Lymphocytes / Q000378:metabolism; D039221:mRNA Cleavage and Polyadenylation Factors / Q000097:blood*
chemical_list: D001549:Benzamides; D016207:Cytokines; D007155:Immunologic Factors; D016898:Interferon-alpha; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha